Covid-19 human challenge trials – can they help?

Ethical concerns around a speed-up strategy

102
human challenge trials
The World Health Organization (WHO) says that these human challenge trials offer preliminary estimates of vaccine’s efficacy and safety. Photo - Pexel

The Covid-19 pandemic caused by the novel coronavirus still poses an extraordinary threat to public health worldwide. According to the WHO, if left unchecked, it could ultimately claim millions of lives worldwide. While other measures such as social distancing can help reduce the spread of the Covid-19, these measures come at substantial social and economic costs disproportionately borne by underprivileged groups. The primary concerns so far for this pandemic include — lack of safe, effective vaccines and treatments, insufficient scientific knowledge regarding pathogenesis, immunity, and transmission rate.

As researchers worldwide race to develop a Covid-19 vaccine, many people have volunteered to take part in a controversial testing method called human challenge trials. These trials involve the deliberate infection of healthy volunteers. These trials are not new and are particularly valuable for testing vaccines, such as early the research with smallpox and malaria that transformed global public health.

The World Health Organization (WHO) says that these human challenge trials offer preliminary estimates of vaccine’s efficacy and safety, “Such trials can be used to compare the efficacy of multiple vaccine candidates and thus [to] select the most promising vaccines for larger studies. Well-designed challenge studies might thus not only accelerate Covid-19 vaccine development but also more likely ensure that the vaccines ultimately deployed are more effective.”

The National Institutes of Health researchers also reported that the human challenge trials have distinct advantages over field studies for discerning correlates of safety, given the precise timing of infection and the ability to measure immune responses at predetermined time points.

Besides, the results obtained from these trials are used to study processes of infection and immunity from their inception — validating tests for Covid-19 immunity, immune protection, and risks of transmission posed by infected individuals.

Ethical concerns of human infection challenge

However, research involving the deliberate infection of healthy volunteers is getting mixed opinions from the industry and experts. While addressing the Indian Council of Medical Research’s international symposium (held in July) on ‘Novel Ideas in Science and Ethics of Vaccines Against Covid-19 Pandemic,’ Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, called these challenge trials ‘not ethical or not justified’ at the moment. According to him, the full health impact of Covid-19 infection is not yet fully understood. There are no highly effective therapies available to cure individuals infected in a challenge study.

Whereas WHO states, “The challenge trials are nonetheless ethically sensitive and must be carefully designed and conducted in order to minimize risk to volunteers and preserve public trust in research.”

WHO explained that the well designed human challenge trials provide one of the most efficient and scientifically powerful tools for testing vaccines, primarily because animal models are not adequately generalizable to humans. For the Covid-19 challenge trials to proceed, the WHO has set eight essential criteria that need to be satisfied.

Sayantan Banerjee, an advisory board member of 1Day Sooner, said, “Once researchers better understand the marks of immunity, they can look for these marks in trials for other vaccines. Challenge trials can also allow researchers to understand the early stages of coronavirus infection and how it spreads through our body.”

He also reported that human challenge trials’ usefulness and necessity are not guaranteed, but these trials could be a valuable tool in fighting the Covid-19 pandemic.

A paper published in The Journal of Infectious Diseases also proposed replacing Phase 3 trials with human challenge trials. “Controlled human challenge trials of Covid-19 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional Phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly.”

Experts in favor of human challenge trials believe that the challenge trials my ultimately prove to be useful. It would be a mistake to delay the preparations further, they say, and could begin right now!

Phase-I clinical trials of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with ICMR and Cadila Healthcare have so far revealed ‘excellent safety.’ Their immunogenicity testing is now in progress, as the minister of State for Health, Ashwini Choubey, informed the Rajya Sabha on 15 September.

Republished from the healthtekpack.com story of 23 September 2020 . Subscribe to the fortnightly Healthtekpak eZine from the IppStar group.

2023 promises an interesting ride for print in India

Indian Printer and Publisher founded in 1979 is the oldest B2B trade publication in the multi-platform and multi-channel IPPGroup. While the print and packaging industries have been resilient in the past 33 months since the pandemic lockdown of 25 March 2020, the commercial printing and newspaper industries have yet to recover their pre-Covid trajectory.

The fragmented commercial printing industry faces substantial challenges as does the newspaper industry. While digital short-run printing and the signage industry seem to be recovering a bit faster, ultimately their growth will also be moderated by the progress of the overall economy. On the other hand book printing exports are doing well but they too face several supply-chain and logistics challenges.

The price of publication papers including newsprint has been high in the past year while availability is diminished by several mills shutting down their publication paper and newsprint machines in the past four years. Indian paper mills are also exporting many types of paper and have raised prices for Indian printers. To some extent, this has helped in the recovery of the digital printing industry with its on-demand short-run and low-wastage paradigm.

Ultimately digital print and other digital channels will help print grow in a country where we are still far behind in our paper and print consumption and where digital is a leapfrog technology that will only increase the demand for print in the foreseeable future. For instance, there is no alternative to a rise in textbook consumption but this segment will only reach normality in the next financial year beginning on 1 April 2023.

Thus while the new normal is a moving target and many commercial printers look to diversification, we believe that our target audiences may shift and change. Like them, we will also have to adapt with agility to keep up with their business and technical information needs.

Our 2023 media kit is ready, and it is the right time to take stock and reconnect with your potential markets and customers. Print is the glue for the growth of liberal education, new industry, and an emerging economy. We seek your participation in what promises to be an interesting ride.

– Naresh Khanna

Subscribe Now

LEAVE A REPLY

Please enter your comment!
Please enter your name here